Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.
Projects from Affini-T, Bolt, Chimeric and Alentis, all hitting novel targets, as well as one from A2 using an old one, are set for first clinical trial entry.
Front-line phase 3 plans take shape, as the company claims a new success, this time in pancreatic cancer.
The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.
A work-stretched US FDA has several key approval application still to review by the end of 2023.
As Tropion-Breast01 is toplined positive Astra ensures the markets know that overall survival isn’t a washout.